We know that,Trastuzumab emtansine (INN, also called trastuzumab-DM1 or trastuzumab-MCC-DM1, abbreviated T-DM1) is an antibody-drug conjugate consisting of the antibody trastuzumab (the active ingredient in Herceptin) linked to a cytotoxic agent that is a derivative of maytansine (DM1).
It is in clinical trials for breast cancer, especially of the HER2 positive type.
Early results in Nov 2011 from an open-label phase II trial on 137
patients with HER2-positive advanced breast cancer were very
encouraging.
EMILIA, a phase III trial of 991 people with HER2-positive
unresectable locally advanced or metastatic breast cancer, comparing
T-DM1 versus capecitabine plus lapatanib in patients previously treated
with trastuzumab and a taxane chemotherapy, showed improved progression
free survival in patients treated with T-DM1 (median 9.6 vs. 6.4 months)
with an improved safety profile. The study sponsor reported in August
2012 that T-DM1 significantly improved survival in the EMILIA study and
that the details will be reported at an upcoming medical meeting
